United States Patent 8,338,642: Ferric Citrate Patent Scope, Claims, Expiration, and Auryxia Patent Landscape

U.S. Patent No. 8,338,642 protects ferric citrate defined by a high BET active surface area, with dependent limits for intrinsic dissolution rate, chemical formula, oral dosage forms, pharmaceutical compositions, and treatment of hyperphosphatemia or metabolic acidosis. The patent is part of the U.S. Auryxia (ferric citrate) patent estate associated with Keryx Biopharmaceuticals and, subsequently, Akebia Therapeutics. Its principal commercial value is the potential to cover ferric citrate tablets that meet the claimed surface-area and dissolution specifications, rather than ferric citrate in every physical form.

What does U.S. Patent 8,338,642 protect?

The patent protects four related categories:

Ferric citrate as a material defined by BET active surface area.
Ferric citrate with a specified intrinsic dissolution rate.
Oral pharmaceutical forms, particularly tablets.
Treatment methods and pharmaceutical compositions using the claimed ferric citrate.

The independent claims are claims 1, 8, 9, 10, 17 and 18.

Claim group	Subject matter	Core limitation
Claim 1	Ferric citrate product	BET active surface area greater than 16 m²/g
Claims 2-4	Product characteristics	Intrinsic dissolution rate, BET range and formula
Claims 5-7	Oral dosage forms	Oral administration, including tablets
Claims 8-9	Treatment methods	Hyperphosphatemia or metabolic acidosis
Claim 10	Pharmaceutical composition	Claimed ferric citrate plus a suitable carrier
Claims 11-16	Composition limitations	Dissolution rate, BET range, formula and dosage form
Claims 17-18	Composition treatment methods	Treatment of hyperphosphatemia or metabolic acidosis

The patent does not claim all ferric citrate. It requires the material to have a BET active surface area above the stated threshold or, for narrower claims, to satisfy additional physical and chemical limitations.

How does the BET surface-area limitation define infringement?

BET active surface area is the central technical limitation in the patent. The Brunauer-Emmett-Teller method measures the specific surface area of a powder, generally in square meters per gram. A ferric citrate batch with a BET active surface area of 16 m²/g or less would not literally satisfy claim 1. A batch above 16 m²/g may satisfy the product limitation, subject to the other claim requirements.

Claim 1: greater than 16 m²/g

Claim 1 requires:

Ferric citrate having a BET active surface area greater than 16 sq. m/g.

This is a product claim. It does not require a particular manufacturing process, supplier, dosage strength or indication. A product claim can create a direct infringement risk if a competing manufacturer makes, uses, sells or imports ferric citrate meeting the limitation in the United States.

The limitation is measurable. A generic applicant or innovator would normally assess representative commercial batches using a validated BET testing protocol. Testing methodology, sample preparation, drying conditions, particle aggregation and batch-to-batch variability can affect the result.

Claims 2 and 11: intrinsic dissolution rate

Claim 2 requires an intrinsic dissolution rate of 1.88 to 4.0 mg/cm²/min. Claim 11 uses a slightly different lower limit of 1.9 mg/cm²/min.

Claim	Intrinsic dissolution rate
Claim 2	1.88-4.0 mg/cm²/min
Claim 11	1.9-4.0 mg/cm²/min

These claims are narrower than claim 1 because the ferric citrate must satisfy both the BET requirement and the dissolution-rate range. A product outside the dissolution range could still infringe claim 1 if its BET active surface area exceeds 16 m²/g.

Claims 3 and 12: BET range of 16-20 m²/g

Claims 3 and 12 state that the BET active surface area ranges from 16 to 20 m²/g. This creates a drafting issue because the parent claims require a BET active surface area “greater than 16” m²/g, while the dependent claims recite a range beginning at 16 m²/g.

Under ordinary claim-dependency principles, a dependent claim must include every limitation of its parent. The practical reading is likely that the operative lower boundary remains greater than 16 m²/g, despite the dependent-claim wording. The exact treatment of the 16.0 m²/g boundary could become relevant in claim construction or validity litigation.

What are the chemical and dosage-form limitations?

Ferric citrate formula

Claims 4 and 13 recite ferric citrate having the formula C6H5O7Fe. This limitation narrows the claims to the stated chemical formula. Ferric citrate can exist with different hydration states, compositions and physical characteristics, so the formula limitation may be relevant when distinguishing ferric citrate materials used in commercial products.

A competitor could attempt to argue that its material is a different ferric iron complex, hydrate, salt or composition. That argument would depend on the actual chemical identity and the claim construction adopted by a court.

Oral dosage forms

Claims 5-7 and 14-16 cover orally administrable forms. The listed forms include:

Tablet
Powder
Suspension
Emulsion
Capsule
Granule
Troche
Pill
Liquid
Spirit
Syrup

The tablet claims have the greatest commercial relevance because Auryxia is marketed as an oral tablet. The dosage-form limitation does not appear to require a specific tablet weight, excipient system, coating, color, imprint or dosing schedule.

What methods of treatment does U.S. Patent 8,338,642 cover?

Claims 8 and 17 cover treatment of hyperphosphatemia. Claims 9 and 18 cover treatment of metabolic acidosis.

Hyperphosphatemia

Claim 8 covers administering ferric citrate with a BET active surface area greater than 16 m²/g to a patient requiring treatment. Claim 17 covers administering a pharmaceutical composition containing that ferric citrate and a suitable carrier.

These claims are relevant to ferric citrate phosphate binders used in patients with chronic kidney disease, including patients on dialysis. The claims do not expressly require a specific dose, dialysis status, treatment duration or administration frequency.

Metabolic acidosis

Claims 9 and 18 cover treatment of metabolic acidosis. This indication is separate from hyperphosphatemia and broadens the potential method-of-use scope. Whether a commercial product label, physician use or generic label practice creates method-of-use exposure depends on the approved indication, labeling language and actual conduct.

What is the FDA and Orange Book status of U.S. Patent 8,338,642?

Auryxia is the branded ferric citrate product associated with U.S. Patent 8,338,642. The FDA approved Auryxia under NDA 205874 in 2014 for control of serum phosphorus levels in adults with chronic kidney disease on dialysis. The FDA later approved an indication for iron deficiency anemia in adults with chronic kidney disease not on dialysis. The product is supplied as ferric citrate tablets; each 1-gram tablet contains 210 mg of ferric iron, according to the prescribing information (U.S. Food and Drug Administration, 2023).

The patent has been listed in the FDA Orange Book for Auryxia-related regulatory protection. Orange Book listing is important because an ANDA applicant must address listed patents through a Paragraph III or Paragraph IV certification. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or not infringed.

The FDA approval itself does not establish that every ferric citrate tablet infringes the patent. The relevant question is whether the proposed generic product satisfies the claimed BET, dissolution, chemical and dosage-form limitations.

When does U.S. Patent 8,338,642 lose exclusivity?

The patent was issued on December 25, 2012. Its effective U.S. term is generally calculated from the relevant nonprovisional filing date, subject to patent-term adjustment and other statutory provisions. Public patent and Orange Book records associate the patent with an expiration date in September 2029, commonly reported as September 18 or September 19, 2029 depending on the record and term calculation (U.S. Patent and Trademark Office, 2012; FDA, 2024).

The principal exclusivity timeline is:

Event	Date
Earliest claimed priority	September 2008
U.S. nonprovisional filing	2009
Patent issued	December 25, 2012
Auryxia FDA approval	September 2014
Expanded anemia indication	2017
Expected patent expiration	September 2029

Patent expiration does not necessarily equal generic launch. A generic applicant may launch before expiration at risk, obtain a license, prevail in litigation, or enter under a settlement date.

Which companies have challenged the Auryxia patent estate?

Auryxia has faced ANDA challenges involving generic-drug manufacturers, including Teva Pharmaceuticals, Lupin, Alembic Pharmaceuticals and Zydus-affiliated applicants. The associated litigation has involved U.S. Patent No. 8,338,642 and other Auryxia patents, including later-issued patents directed to ferric citrate compositions, formulations or uses.

The presence of a Paragraph IV challenge does not mean that the challenger has invalidated the patent. It means the applicant has notified the patent holder of its legal position and may trigger patent litigation under the Hatch-Waxman Act.

Keryx and Akebia have pursued infringement actions in the U.S. District Court for the District of Delaware against ANDA applicants. The cases have involved standard disputes over:

Whether the proposed generic ferric citrate satisfies the BET limitation.
Whether the generic product meets the claimed dissolution rate.
Whether the patent claims are anticipated or obvious.
Whether the claims adequately describe and enable the claimed material.
Whether the proposed labeling induces infringement of treatment claims.
Whether later Auryxia patents provide additional barriers after the 642 patent expires.

What generic entry risks exist for ferric citrate?

Generic entry risk is substantial but technically fact-dependent. The main scenarios are as follows.

Entry after patent expiration

A generic applicant may launch after the September 2029 expiration date if no other enforceable patent or regulatory exclusivity blocks approval. This is the lowest litigation-risk pathway.

Settlement-based entry

A Paragraph IV settlement may permit an agreed launch before patent expiration. The commercial date would depend on the settlement terms, other Orange Book patents and any exclusivity held by a first Paragraph IV filer.

At-risk launch

A challenger could launch before final resolution of the patent dispute. That would expose the applicant to damages and a possible injunction if the patent is later upheld and found infringed.

Non-infringing formulation or process

A generic manufacturer may attempt to formulate ferric citrate with a BET active surface area at or below the claimed threshold, or outside the dissolution-rate range. This strategy carries regulatory and pharmaceutical-equivalence risks because changes in surface area can affect dissolution, phosphate binding and product performance.

How strong is the patent estate for U.S. Patent 8,338,642?

The patent has meaningful commercial scope but several litigation pressure points.

Issue	Assessment
Product claim	Stronger than a pure method claim if the physical property is reliably measurable
BET limitation	Provides a concrete infringement test but creates testing and variability disputes
Dissolution claims	Narrower and more vulnerable to non-infringement based on measured performance
Formula claim	Can distinguish alternative ferric compounds but may face chemistry-based claim-construction disputes
Tablet claims	Commercially important for Auryxia but narrower than the base product claim
Treatment claims	Potentially broad, but inducement depends on labeling and evidence of intended use
Validity risk	Likely centered on obviousness, enablement, written description and prior ferric citrate materials
Design-around risk	A competitor may target surface area or dissolution outside the claimed ranges

The strongest commercial claim is likely claim 1 because it covers the ferric citrate material without requiring a tablet or a particular indication. The strongest practical defense for a generic applicant would be a reliable demonstration that its product does not meet the BET threshold or, where relevant, the dissolution-rate range.

What manufacturing and intellectual-property barriers apply?

The patent creates a manufacturing-control issue rather than a conventional synthesis-process barrier. A manufacturer must control powder morphology, particle size, porosity, aggregation and processing conditions sufficiently to produce a consistent BET surface area.

The same characteristics that support high surface area can affect:

Dissolution rate
Chemical stability
Tablet compression
Excipient compatibility
Bioavailability or local gastrointestinal performance
Phosphate-binding behavior
Batch release testing

A design-around that reduces surface area could avoid claim 1 but may alter the product's pharmaceutical performance. Conversely, an apparently equivalent generic process may still produce a BET surface area above 16 m²/g, creating infringement risk even if the manufacturing route differs.

How does the patent compare with competing ferric citrate and phosphate-binder estates?

Auryxia competes primarily with phosphate binders such as sevelamer, calcium acetate, lanthanum carbonate and sucroferric oxyhydroxide. These products have different active ingredients and patent estates.

Product	Active ingredient	Main regulatory pathway	Relationship to U.S. 8,338,642
Auryxia	Ferric citrate	NDA	Directly relevant
Renvela/Renagel	Sevelamer	NDA	No direct chemical overlap
PhosLo	Calcium acetate	NDA or legacy pathways	No direct chemical overlap
Fosrenol	Lanthanum carbonate	NDA	No direct chemical overlap
Velphoro	Sucroferric oxyhydroxide	NDA	No direct chemical overlap

Auryxia has no biosimilar pathway because ferric citrate is a small-molecule chemical product, not a biologic. Generic competition proceeds through an ANDA, not a biosimilar application under the Public Health Service Act.

What licensing deals affect the ferric citrate patent landscape?

Keryx commercialized ferric citrate in the United States after obtaining rights connected with the ferric citrate development program from Panion & BF Biotech. Keryx later became part of Akebia Therapeutics, which assumed control of the Auryxia commercial and intellectual-property portfolio. Those transactions affect ownership and commercial control but do not independently extend the statutory patent term.

Licenses and settlements may still affect generic launch timing, territory, authorized-generic strategy and royalty economics. The operative terms must be evaluated patent by patent because a settlement covering one Auryxia patent may not resolve later-issued patents.

Key Takeaways

U.S. Patent 8,338,642 centers on ferric citrate with a BET active surface area greater than 16 m²/g.
The patent also claims specified intrinsic dissolution rates, the formula C6H5O7Fe, oral dosage forms, tablets, pharmaceutical compositions and treatment of hyperphosphatemia or metabolic acidosis.
Claim 1 is the principal commercial product claim.
Claims 3 and 12 contain a drafting tension between “greater than 16” and a dependent range beginning at 16 m²/g.
Auryxia is an FDA-approved ferric citrate tablet associated with the patent estate.
The patent is generally reported to expire in September 2029.
Teva, Lupin, Alembic and Zydus-affiliated applicants have been involved in reported Auryxia ANDA patent challenges.
No biosimilar pathway applies. Generic entry requires an ANDA.
The key technical dispute is likely whether a proposed generic product meets the BET surface-area limitation under a reproducible testing protocol.
Later Auryxia patents and settlement agreements may affect generic entry even after the 642 patent is resolved.

Frequently Asked Questions

Does U.S. Patent 8,338,642 cover all ferric citrate products?

No. The claims require ferric citrate with a BET active surface area greater than 16 m²/g or additional limitations derived from that requirement.

Can a generic avoid the patent by using a different manufacturing process?

Possibly. Patent infringement generally turns on whether the accused product satisfies the claim limitations, not whether it uses the same manufacturing process. A different process does not avoid infringement if the resulting ferric citrate meets the claimed characteristics.

Is Auryxia protected by a biologic patent or biosimilar exclusivity?

No. Auryxia is a small-molecule ferric citrate product. Its competitors would use the ANDA pathway for generic approval rather than the biosimilar pathway.

Does a Paragraph IV filing immediately permit a generic launch?

No. The patent holder may sue, triggering a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court decisions.

What laboratory test is most important in assessing infringement?

The BET active surface-area test is the principal test for claim 1. Intrinsic dissolution testing becomes important for claims 2, 11 and related dependent claims.

References

Akebia Therapeutics, Inc. (2023). Auryxia (ferric citrate) tablets: Prescribing information. U.S. Food and Drug Administration.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2014). Auryxia approval history and labeling for NDA 205874. https://www.fda.gov/
U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,338,642: Ferric citrate compositions and methods of use. https://patents.google.com/patent/US8338642
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent application information for U.S. Patent No. 8,338,642. https://patents.google.com/ ━

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004213819	⤷ Start Trial
Australia	2006279333	⤷ Start Trial
Australia	2007210090	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,338,642

Summary for Patent: 8,338,642